[
  {
    "ts": null,
    "headline": "More Drugs to Fight High Cholesterol Are Emerging",
    "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
    "url": "https://finnhub.io/api/news?id=fc4cccd5844bc150d3d155db22cb5e7fe5a1ea353738d6e1b38aabebe8281e65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762640880,
      "headline": "More Drugs to Fight High Cholesterol Are Emerging",
      "id": 137384575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
      "url": "https://finnhub.io/api/news?id=fc4cccd5844bc150d3d155db22cb5e7fe5a1ea353738d6e1b38aabebe8281e65"
    }
  },
  {
    "ts": null,
    "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
    "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
    "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762630245,
      "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
      "id": 137384576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
      "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
    "summary": "RAHWAY, N.J., November 08, 2025--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
    "url": "https://finnhub.io/api/news?id=a7895a3880157f297d114a90f2d91e78fc1b261f05583b92e29bf0d892ea9c4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762630200,
      "headline": "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
      "id": 137384577,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., November 08, 2025--Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial",
      "url": "https://finnhub.io/api/news?id=a7895a3880157f297d114a90f2d91e78fc1b261f05583b92e29bf0d892ea9c4a"
    }
  },
  {
    "ts": null,
    "headline": "How To Prepare For The Market Top",
    "summary": "Read about how a bucket-based portfolio strategy can help retirees invest near market highs with diversification, reduced risk, and steady growth.",
    "url": "https://finnhub.io/api/news?id=e6f129ce597cb66381a61f5907fe35d1998c4fe61d2da42ded56a0058480c94c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762589100,
      "headline": "How To Prepare For The Market Top",
      "id": 137378179,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2163675219/image_2163675219.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read about how a bucket-based portfolio strategy can help retirees invest near market highs with diversification, reduced risk, and steady growth.",
      "url": "https://finnhub.io/api/news?id=e6f129ce597cb66381a61f5907fe35d1998c4fe61d2da42ded56a0058480c94c"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now. On November 3, Morg⁠an Stanley anal‌yst Tere‍nce Flynn‍ raised the price target for Merck & Co., Inc. (NYSE:MRK) from​ $98​ to $100 while maintaining an Equal Wei⁠g‍ht rating.​ He noted that third⁠-qu⁠arter re‍sults beat‌ exp‌ectations‍, largely due to […]",
    "url": "https://finnhub.io/api/news?id=c77f8ef199ec220688a489df26d1aca14d79ca3bb633cd3a7e8209c3e8ee958a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762581446,
      "headline": "Morgan Stanley Raises Merck (MRK) Price Target to $100, Maintains Equal Weight Rating",
      "id": 137378374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co., Inc. (NYSE:MRK) is included among the 15 Best DRIP Stocks to Own Right Now. On November 3, Morg⁠an Stanley anal‌yst Tere‍nce Flynn‍ raised the price target for Merck & Co., Inc. (NYSE:MRK) from​ $98​ to $100 while maintaining an Equal Wei⁠g‍ht rating.​ He noted that third⁠-qu⁠arter re‍sults beat‌ exp‌ectations‍, largely due to […]",
      "url": "https://finnhub.io/api/news?id=c77f8ef199ec220688a489df26d1aca14d79ca3bb633cd3a7e8209c3e8ee958a"
    }
  }
]